Literature DB >> 9195564

Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma.

M Hasegawa1, M Takata, N Hatta, K Wakamatsu, S Ito, K Takehara.   

Abstract

Serum 5-S-cysteinyl dopa (5-S-CD), circulating intercellular adhesion molecule-1 (cICAM-1) and soluble interleukin-2 receptor (sIL-2R) have each been reported as useful markers for melanoma progression. To assess the clinical relevance of these three markers, we simultaneously assayed their serum levels in 30 Japanese melanoma patients. Pre-surgical serum levels of 5-S-CD, cICAM-1 and sIL-2R were elevated in six, 13 and five patients respectively. These abnormal values returned to normal after curative surgery in most of the patients, suggesting a direct relationship to the presence of the primary tumour. Pre-surgical values of these three markers, either individually or in combination, did not predict the development of subsequent metastases. The sequential measurements of the three markers in eight patients who had relapse after surgery showed that serum 5-S-CD is the most useful marker for disease progression, although it is dependent on the melanin-producing ability of individual recurrent tumours. sIL-2R seemed to reflect in vivo activation of the host immune system and was a good indicator for predicting occult metastasis in selected cases. Circulating ICAM-1 levels were less relevant to the clinical disease course in our cases, although they tended to increase strikingly after liver metastasis. Our results in this limited number of cases show that the significance of the three markers varied with the individual and suggest that the simultaneous measurement of these markers may facilitate the early detection of metastases and proper therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195564     DOI: 10.1097/00008390-199706000-00009

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

1.  Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.

Authors:  T Bánfalvi; K Gilde; M Boldizsár; T Kremmer; S Ottó
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Malignant melanoma of the male urethra with increased 5-S-cysteinyldopa: A case report.

Authors:  Yusuke Aoki; Takahiko Soma; Yuki Nakamura; Naotaka Fukui; Yasuyuki Sakai; Yukio Kageyama
Journal:  IJU Case Rep       Date:  2019-06-11

3.  Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.

Authors:  Teodóra Bánfalvi; Mariann Boldizsár; Maria Gergye; Katalin Gilde; Tibor Kremmer; Szabolcs Ottó
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

4.  A synopsis of serum biomarkers in cutaneous melanoma patients.

Authors:  Pierre Vereecken; Frank Cornelis; Nicolas Van Baren; Valérie Vandersleyen; Jean-François Baurain
Journal:  Dermatol Res Pract       Date:  2012-01-12

Review 5.  Significance of 5-S-Cysteinyldopa as a Marker for Melanoma.

Authors:  Kazumasa Wakamatsu; Satoshi Fukushima; Akane Minagawa; Toshikazu Omodaka; Tokimasa Hida; Naohito Hatta; Minoru Takata; Hisashi Uhara; Ryuhei Okuyama; Hironobu Ihn
Journal:  Int J Mol Sci       Date:  2020-01-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.